Insider sales and ownership changes
On March 11, 2026, Chad M. Robins, Adaptive Biotechnologies' CEO and Chairman, sold a combined 470,167 shares of the company’s common stock at a price of $13.17 per share. The two transactions together totaled approximately $6.19 million.
The first disposition was for 140,567 shares, recorded at $1,851,267. Following that sale, Robins was reported to directly own 2,630,713 shares of Adaptive Biotechnologies. The second transaction covered 329,600 shares, valued at $4,340,832, and left Robins with 2,301,113 shares outstanding.
Why the sales occurred
Footnotes in the related SEC filing specify these sales were executed to meet tax withholding obligations arising from the vesting of restricted stock units and performance share units. The filing characterizes the dispositions as mandated by Adaptive Biotechnologies’ equity incentive plans and explicitly notes they were not discretionary trades initiated by Robins.
Market context and valuation note
The stock traded in a volatile fashion recently, having fallen 11.37% over the past week while remaining higher by 80.91% over the last 12 months. An InvestingPro analysis cited in the filings indicates the stock currently appears overvalued relative to its Fair Value.
Recent operating results and analyst response
In other company disclosures, Adeptus Biotechnologies reported fourth-quarter 2025 results that exceeded analyst expectations on both the earnings and revenue lines. The company recorded earnings per share of -$0.09 versus an anticipated -$0.18, and posted revenue of $71.7 million, which was 20.85% above the projected $59.33 million.
Following the earnings release, several broker-dealers adjusted their positions. Piper Sandler reaffirmed an Overweight rating on the stock. TD Cowen raised its price target from $20.00 to $21.00, while BTIG lifted its target to $22.00, citing robust growth in the company’s Minimal Residual Disease, or MRD, business.
The MRD segment showed a 54% year-over-year increase in the fourth quarter and delivered a 46% revenue gain for the full year. Piper Sandler highlighted the company’s standing in the MRD market for hematological malignancies and projected clonoSEQ volume growth above 30%.
Despite the results and analyst updates, the stock registered a slight decline in aftermarket trading.
Further information
For investors seeking more detailed valuation and financial analysis, the filings note a comprehensive Pro Research Report is available for this company and more than 1,400 other U.S. equities through InvestingPro.